MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson's Disease - MeiraGTx Hldgs ( NASDAQ:MGTX )

3 days ago

The primary study objective of safety and tolerability was met Significant and clinically meaningful improvements from baseline demonstrated for key efficacy endpoints at 26 weeks Significant improvement of 18 points in Unified Parkinson's Disease Rating Scale ( UPDRS ) Part 3 in the high dose ...

Ticker	Sentiment	Impact
MGTX	Neutral	25 %